TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition
Authors
Keywords
-
Journal
ONCOGENE
Volume 35, Issue 21, Pages 2684-2686
Publisher
Springer Nature
Online
2015-10-05
DOI
10.1038/onc.2015.374
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials
- (2015) Chiara Ciccarese et al. CANCER TREATMENT REVIEWS
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
- (2015) I. Watermann et al. Diagnostic Pathology
- Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
- (2015) Maeva Dufies et al. Oncotarget
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer
- (2014) T. Yoshida et al. CLINICAL CANCER RESEARCH
- Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics
- (2014) Min-Sik Kim et al. MOLECULAR & CELLULAR PROTEOMICS
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The emerging role of MET/HGF inhibitors in oncology
- (2013) Giorgio V. Scagliotti et al. CANCER TREATMENT REVIEWS
- The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors – Is there more to come?
- (2013) Viktor Grünwald et al. EUROPEAN JOURNAL OF CANCER
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
- (2010) Rachel MA Linger et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
- (2008) M. L. Nickerson et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started